Martin G. Sanda, MD

Publications

• Hayn MH, Orom H, Shavers VL, Sanda MG, Glasgow M, Mohler JL, Underwood W.Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer.Cancer. 2011 Mar 31.
  21456009
• Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA.A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prost
  21419439
• Kazer MW, Harden J, Burke M, Sanda MG, Hardy J, Bailey DE, .The experiences of unpartnered men with prostate cancer: a qualitative analysis.J Cancer Surviv. 2010 Nov 28.
  21113818
• Sanda MG.Editorial comment. Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131.Urology. 2010 Nov;76(5):1148; author reply 1148-9.
  21056260
• Szymanski KM, Wei JT, Dunn RL, Sanda MG.Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument for Measuring Health-related Quality of Life Among Prostate Cancer Survivors.Urology. 2010 Nov;76(5):12
  20350762
• Sanda MG.Urinary Obstructive Problems Exposed But Hormonal Health-Related Quality-of-Life Concerns Eschewed in Prostate Cancer Quality-of-Life Study.J Clin Oncol. 2010 Nov 1;28(31):4667-8.
  20921452
• Levinson AW, Ward NT, Sanda MG, Mettee LZ, Wei JT, Su LM, Litwin MS, Pavlovich CP.Comparison of validated instruments measuring sexual function in men.Urology. 2010 Aug;76(2):380-6.
  20573377
• Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, Exley MA.Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide.PLoS ONE. 2010;5(6):e11311.
  20593019
• Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL.The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer.BJU Int. 2010 May;105(10):1417-22. Review.
  20346051
• Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, Escara-Wilke J, Leander KR, Defeo-Jones D, Hwang C, Sanda MG.Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.Prostate. 2010 Jun 15;70(9):1002-11.
  20209643
• Sandler HM, Liu PY, Dunn RL, Khan DC, Tropper SE, Sanda MG, Mantz CA.Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagn
  20153881
• Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW.A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate can
  20447916
• Aronovitz JA, Sanda MG.Further perspectives on treating localized prostate cancer.Oncology (Huntingt). 2009 Oct;23(11):964, 966.
  19947348
• Eyre SJ, Ankerst DP, Wei JT, Nair PV, Regan MM, Bueti G, Tang J, Rubin MA, Kearney M, Thompson IM, Sanda MG.Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.J Urol
  19836788
• Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG.Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.Urology. 2009 Nov;74(5):1156-61.
  19647299
• Shappley WV, Kenfield SA, Kasperzyk JL, Qiu W, Stampfer MJ, Sanda MG, Chan JM.Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.J Clin Oncol. 2009 Oct 20;27(30):4
  19720918
• Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG.Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.Clin
  19737960
• Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy i
  19584163
• Sanda MG.Editorial comment. Nerve sparing during radical prostatectomy is associated with better recovery of urinary continence.Urology. 2009 Jun;73(6):1340-1; author reply 1341.
  19482155
• Sanda MG.Editorial Comments.J Urol. 2009 May 16.
  19450850
• Sanda MG,Kaplan ID.A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment.JAMA. 2009 May 27;301(20):2141-51.
  19417179
• Sanda MG.Live longer but not better...yet.Lancet Oncol. 2009 Apr;10(4):313-4.
  19341967
• McDermott DW,Sanda MG.Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4.Nat Clin Pract Urol. 2009 Mar;6(3):124-5.
  19190593
• Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda M, Vaishampayan U, Petrylak DP, Quinn DI, Beekman K, Montie JE.Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.J Urol. 200
  18930256
• Kershaw TS,Mood DW,Newth G,Ronis DL,Sanda MG,Vaishampayan U,Northouse LL.Longitudinal analysis of a model to predict quality of life in prostate cancer patients and their spouses.Ann Behav Med. 2008 Oct;36(2):117-28.
  18830672
• Hu JC,Hevelone ND,Ferreira MD,Lipsitz SR,Choueiri TK,Sanda MG,Earle CC.Patterns of care for radical prostatectomy in the United States from 2003 to 2005.J Urol. 2008 Nov;180(5):1969-74.
  18801512
• Haram KM,Peltier HJ,Lu B,Bhasin M,Otu HH,Choy B,Regan M,Libermann TA,Latham GJ,Sanda MG,Arredouani MS.Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclin
  18668517
• Hollenbeck BK,Dunn RL,Wolf JS Jr,Sanda MG,Wood DP,Gilbert SM,Weizer AZ,Montie JE,Wei JT.Development and validation of the convalescence and recovery evaluation (CARE) for measuring quality of life after surgery.Qual Life Res. 2008 Aug;17(6):915-26.
  18574712
• Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG.Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.Cancer Immunol Immunother. 2008 Sep;57(9):1357-65.
  18265979
• Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW.[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.J Urol. 2008 Aug;180(2):539-
  18550118
• Mosquera JM,Perner S,Genega EM,Sanda M,Hofer MD,Mertz KD,Paris PL,Simko J,Bismar TA,Ayala G,Shah RB,Loda M,Rubin MA.Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.Clin Cancer Res.
  18519767
• Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG.Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.Prostate. 2008 May 15;68(7):715-27.
  18302222
• Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT.Quality of life and satisfaction with outcome a
  18354103
• Adey GS, Pedrosa I, Rofsky NM, Sanda MG, DeWolf WC.Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms.Urology. 2008 Jan;71(1):47-51.
  18242363